Pursuant to Regulation 29 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, Wanbury has informed that the meeting of the Board of Directors of the company is scheduled to be held on Thursday, 16th May, 2024, to consider and approve the Audited Financial Results & Statements (Standalone & Consolidated) for the fourth quarter and financial year ended 31st March, 2024. Further, as per Securities and Exchange Board of India (Prohibition of Insider Trading) Regulations, 2015, the trading window for dealing in Securities of the Company shall remain closed until the expiry of 48 hours after the declaration of the said Financial Results. The above intimation is also available on the website of the Company at www.wanbury.com and on the website of BSE at www.bseindia.com and the National Stock Exchange of India at www.nseindia.com.
The above information is a part of company’s filings submitted to BSE.
| Company Name | CMP |
|---|---|
| Sun Pharma Inds. | 1675.20 |
| Dr. Reddys Lab | 1235.40 |
| Cipla | 1238.30 |
| Zydus Lifesciences | 942.55 |
| Lupin | 2324.25 |
| View more.. | |
MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.
To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.
MoneyWorks4Me ensures this through: